Bone morphogenetic protein 2 receptor (BMPR) (BMPR)

Bone morphogenetic protein 2 (BMP2) receptors are transmembrane serine/threonine kinases belonging to the TGF-beta receptor superfamily, primarily composed of Type I (BMPR1A/ALK3) and Type II (BMPR2) subunits (UniProt P36894, Q13873). Upon ligand binding, these receptors initiate a signaling cascade that phosphorylates Smad1/5/8 proteins, which subsequently translocate to the nucleus to induce the expression of the Distal-Less Homeobox 3 (DLX3) transcription factor (PubMed: 15901767). The BMP2–DLX3 osteogenic pathway is a critical regulator of bone formation, as DLX3 orchestrates the transition of mesenchymal stem cells into osteoblasts and regulates the synthesis of the bone matrix (PubMed: 21828254). Mutations in DLX3 are the primary cause of Tricho-dento-osseous (TDO) syndrome, a genetic disorder characterized by increased bone density and dental defects (NIH: Genetic and Rare Diseases Information Center). In clinical practice, recombinant human BMP-2 (rhBMP-2), such as dibotermin alfa, is used to stimulate bone growth in spinal fusions and tibial non-unions by activating this receptor complex (FDA: Infuse Bone Graft). However, therapeutic use is associated with risks such as ectopic ossification and significant localized inflammatory responses (PubMed: 24563734). The pathway also plays a role in pulmonary arterial hypertension, where mutations in BMPR2 lead to abnormal vascular cell proliferation (UniProt Q13873). Research into small molecule modulators of this pathway continues to target bone regenerative medicine and metabolic bone diseases.

Other names

BMP2 receptorBMPR1ABMPR2ALK3BMP2-DLX3 axisBone morphogenetic protein receptor type 1ABone morphogenetic protein receptor type 2

Agonism of the BMP2 receptor complex (BMPR1A/BMPR2) triggers Smad-mediated transcription of DLX3, which promotes the differentiation of mesenchymal stem cells into osteoblasts and stimulates bone matrix production.